NCT06247605View on ClinicalTrials.gov

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2029

Conditions
Small Cell Lung Carcinoma
Interventions
DRUG

AL8326 tablets

10mg/tablet, Oral administration, once daily.

DRUG

placebo

Oral administration, once daily.

Trial Locations (1)

130000

RECRUITING

JILIN Cancer Hospital, Changchun

Sponsors
All Listed Sponsors
lead

Advenchen Laboratories Nanjing Ltd.

INDUSTRY